Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma

Yutaka Kawakami, Nita Dang, Xiang Wang, Janis Tupesis, Paul F. Robbins, Rong Fu Wang, John R. Wunderlich, John R. Yannelli, Steven A. Rosenberg

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

A total of 123 tumor-infiltrating T lymphocyte (TIL) cultures established from patients with HLA-A1, -A2, -A3, -A24, or -A31 metastatic melanoma in the Surgery Branch, National Cancer Institute, were screened for recognition of shared melanoma antigens including five melanosomal proteins (tyrosinase, MART-1/melan-A, gp100, TRP1, TRP2) as well as peptides derived from MAGE-1 and MAGE-3. Examination of the specificity of these T cells indicated that 16% of HLA-A1 TIL, 57% of HLA-A2 TIL, 7% of HLA-A3 TIL, 13% of HLA-A24 TIL, and 27% of HLA-A31 TIL recognized shared melanoma antigens restricted by major histocompatibility complex class I. Melanosomal proteins were frequently recognized by these TIL, and MART- 127-35, gp100154- 162, gp100209-217, and gp100280-288 represent highly immunogenic epitopes that were recognized by a high percentage of HLA-A2 restricted melanoma reactive TIL. Recognition of gp100 by HLA-A2 restricted TIL significantly correlated with clinical response to adoptive immunotherapy with TIL in 21 HLA-A2 melanoma patients (p = 0.024). Four HLA-A1, two HLA-A2, two HLA-A3, one HLA-A24, and two HLA-A31 restricted shared antigen-specific TIL did not recognize the previously identified antigens tested in this study, and may be useful for the identification of new melanoma antigens. The observation that TILs isolated from patients with metastatic melanoma recognized melanosomal proteins in the context of predominant HLA-A alleles implies that it may be possible to develop immunotherapies for patients with melanoma expressing diverse HLA types.

Original languageEnglish
Pages (from-to)17-27
Number of pages11
JournalJournal of Immunotherapy
Volume23
Issue number1
DOIs
Publication statusPublished - 2000

Fingerprint

Melanoma-Specific Antigens
Tumor-Infiltrating Lymphocytes
HLA-A Antigens
Melanoma
Alleles
HLA-A2 Antigen
T-Lymphocytes
HLA-A1 Antigen
HLA-A24 Antigen
HLA-A3 Antigen
MART-1 Antigen
T-Cell Antigen Receptor Specificity
Adoptive Immunotherapy
Antigens
Proteins
Monophenol Monooxygenase
National Cancer Institute (U.S.)
Major Histocompatibility Complex
Immunotherapy
Epitopes

Keywords

  • HLA-A alleles
  • Melanoma antigens
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. / Kawakami, Yutaka; Dang, Nita; Wang, Xiang; Tupesis, Janis; Robbins, Paul F.; Wang, Rong Fu; Wunderlich, John R.; Yannelli, John R.; Rosenberg, Steven A.

In: Journal of Immunotherapy, Vol. 23, No. 1, 2000, p. 17-27.

Research output: Contribution to journalArticle

Kawakami, Y, Dang, N, Wang, X, Tupesis, J, Robbins, PF, Wang, RF, Wunderlich, JR, Yannelli, JR & Rosenberg, SA 2000, 'Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma', Journal of Immunotherapy, vol. 23, no. 1, pp. 17-27. https://doi.org/10.1097/00002371-200001000-00004
Kawakami, Yutaka ; Dang, Nita ; Wang, Xiang ; Tupesis, Janis ; Robbins, Paul F. ; Wang, Rong Fu ; Wunderlich, John R. ; Yannelli, John R. ; Rosenberg, Steven A. / Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. In: Journal of Immunotherapy. 2000 ; Vol. 23, No. 1. pp. 17-27.
@article{528e2108d8f440ac98d94cd5bd77cbdd,
title = "Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma",
abstract = "A total of 123 tumor-infiltrating T lymphocyte (TIL) cultures established from patients with HLA-A1, -A2, -A3, -A24, or -A31 metastatic melanoma in the Surgery Branch, National Cancer Institute, were screened for recognition of shared melanoma antigens including five melanosomal proteins (tyrosinase, MART-1/melan-A, gp100, TRP1, TRP2) as well as peptides derived from MAGE-1 and MAGE-3. Examination of the specificity of these T cells indicated that 16{\%} of HLA-A1 TIL, 57{\%} of HLA-A2 TIL, 7{\%} of HLA-A3 TIL, 13{\%} of HLA-A24 TIL, and 27{\%} of HLA-A31 TIL recognized shared melanoma antigens restricted by major histocompatibility complex class I. Melanosomal proteins were frequently recognized by these TIL, and MART- 127-35, gp100154- 162, gp100209-217, and gp100280-288 represent highly immunogenic epitopes that were recognized by a high percentage of HLA-A2 restricted melanoma reactive TIL. Recognition of gp100 by HLA-A2 restricted TIL significantly correlated with clinical response to adoptive immunotherapy with TIL in 21 HLA-A2 melanoma patients (p = 0.024). Four HLA-A1, two HLA-A2, two HLA-A3, one HLA-A24, and two HLA-A31 restricted shared antigen-specific TIL did not recognize the previously identified antigens tested in this study, and may be useful for the identification of new melanoma antigens. The observation that TILs isolated from patients with metastatic melanoma recognized melanosomal proteins in the context of predominant HLA-A alleles implies that it may be possible to develop immunotherapies for patients with melanoma expressing diverse HLA types.",
keywords = "HLA-A alleles, Melanoma antigens, Tumor-infiltrating lymphocytes",
author = "Yutaka Kawakami and Nita Dang and Xiang Wang and Janis Tupesis and Robbins, {Paul F.} and Wang, {Rong Fu} and Wunderlich, {John R.} and Yannelli, {John R.} and Rosenberg, {Steven A.}",
year = "2000",
doi = "10.1097/00002371-200001000-00004",
language = "English",
volume = "23",
pages = "17--27",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma

AU - Kawakami, Yutaka

AU - Dang, Nita

AU - Wang, Xiang

AU - Tupesis, Janis

AU - Robbins, Paul F.

AU - Wang, Rong Fu

AU - Wunderlich, John R.

AU - Yannelli, John R.

AU - Rosenberg, Steven A.

PY - 2000

Y1 - 2000

N2 - A total of 123 tumor-infiltrating T lymphocyte (TIL) cultures established from patients with HLA-A1, -A2, -A3, -A24, or -A31 metastatic melanoma in the Surgery Branch, National Cancer Institute, were screened for recognition of shared melanoma antigens including five melanosomal proteins (tyrosinase, MART-1/melan-A, gp100, TRP1, TRP2) as well as peptides derived from MAGE-1 and MAGE-3. Examination of the specificity of these T cells indicated that 16% of HLA-A1 TIL, 57% of HLA-A2 TIL, 7% of HLA-A3 TIL, 13% of HLA-A24 TIL, and 27% of HLA-A31 TIL recognized shared melanoma antigens restricted by major histocompatibility complex class I. Melanosomal proteins were frequently recognized by these TIL, and MART- 127-35, gp100154- 162, gp100209-217, and gp100280-288 represent highly immunogenic epitopes that were recognized by a high percentage of HLA-A2 restricted melanoma reactive TIL. Recognition of gp100 by HLA-A2 restricted TIL significantly correlated with clinical response to adoptive immunotherapy with TIL in 21 HLA-A2 melanoma patients (p = 0.024). Four HLA-A1, two HLA-A2, two HLA-A3, one HLA-A24, and two HLA-A31 restricted shared antigen-specific TIL did not recognize the previously identified antigens tested in this study, and may be useful for the identification of new melanoma antigens. The observation that TILs isolated from patients with metastatic melanoma recognized melanosomal proteins in the context of predominant HLA-A alleles implies that it may be possible to develop immunotherapies for patients with melanoma expressing diverse HLA types.

AB - A total of 123 tumor-infiltrating T lymphocyte (TIL) cultures established from patients with HLA-A1, -A2, -A3, -A24, or -A31 metastatic melanoma in the Surgery Branch, National Cancer Institute, were screened for recognition of shared melanoma antigens including five melanosomal proteins (tyrosinase, MART-1/melan-A, gp100, TRP1, TRP2) as well as peptides derived from MAGE-1 and MAGE-3. Examination of the specificity of these T cells indicated that 16% of HLA-A1 TIL, 57% of HLA-A2 TIL, 7% of HLA-A3 TIL, 13% of HLA-A24 TIL, and 27% of HLA-A31 TIL recognized shared melanoma antigens restricted by major histocompatibility complex class I. Melanosomal proteins were frequently recognized by these TIL, and MART- 127-35, gp100154- 162, gp100209-217, and gp100280-288 represent highly immunogenic epitopes that were recognized by a high percentage of HLA-A2 restricted melanoma reactive TIL. Recognition of gp100 by HLA-A2 restricted TIL significantly correlated with clinical response to adoptive immunotherapy with TIL in 21 HLA-A2 melanoma patients (p = 0.024). Four HLA-A1, two HLA-A2, two HLA-A3, one HLA-A24, and two HLA-A31 restricted shared antigen-specific TIL did not recognize the previously identified antigens tested in this study, and may be useful for the identification of new melanoma antigens. The observation that TILs isolated from patients with metastatic melanoma recognized melanosomal proteins in the context of predominant HLA-A alleles implies that it may be possible to develop immunotherapies for patients with melanoma expressing diverse HLA types.

KW - HLA-A alleles

KW - Melanoma antigens

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0033949981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033949981&partnerID=8YFLogxK

U2 - 10.1097/00002371-200001000-00004

DO - 10.1097/00002371-200001000-00004

M3 - Article

C2 - 10687134

AN - SCOPUS:0033949981

VL - 23

SP - 17

EP - 27

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 1

ER -